Hlh Protocol

Disclaimer: This clinical reference is intended for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinicians must exercise their independent medical judgment and consider individual patient circumstances. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to patient care. Drug dosages and protocols may vary based on local guidelines and patient factors; always verify with current prescribing information and institutional protocols.

---

Overview

• Definition: Hemophagocytic Lymphohistiocytosis (HLH) is a rare, life-threatening syndrome of severe systemic hyperinflammation resulting from uncontrolled and ineffective immune activation. It is characterized by persistent activation of macrophages and cytotoxic T cells, leading to excessive cytokine production ("cytokine storm") and widespread tissue damage, often with evidence of hemophagocytosis (macrophages engulfing blood cells) in the bone marrow or other tissues.

• Epidemiology:

  • Overall Incidence: Estimated at 1 in 50,000 to 1 in 100,000 live births for primary/familial HLH, but likely underestimated. Secondary HLH (sHLH) is more common, particularly in adults, and its true incidence is difficult to ascertain due to its association with other conditions.
  • Age Distribution: Primary HLH typically presents in infancy or early childhood (median age < 1 year). Secondary HLH can occur at any age but is more common in older children and adults.
  • Geographic/Ethnic: No significant geographical or ethnic predisposition identified for primary HLH, though certain genetic mutations might be more prevalent in specific populations.

• Classification: HLH is broadly classified into two main types:

  1. Primary (Familial/Genetic) HLH: Caused by germline genetic mutations that impair the function of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. These defects lead to an inability to clear activated immune cells and infected cells, perpetuating inflammation.
     • Subtypes: FHL1-5 based on genetic loci (PRF1, UNC13D, STXBP2, STX11, RAB27A), X-linked lymphoproliferative disease (XLP1, XLP2) due to SH2D1A or XIAP mutations, and other primary immunodeficiencies with HLH features (e.g., Chediak-Higashi, Griscelli, Hermansky-Pudlak syndromes).
  2. Secondary (Acquired) HLH: Occurs in individuals without known underlying genetic defects, usually triggered by severe systemic insults that overwhelm a normal immune system or unmask a predisposition.
     • Associated Conditions:
       • Infection-associated HLH (IA-HLH): Most commonly Epstein-Barr Virus (EBV), but also CMV, HIV, other viruses, bacteria, fungi, and parasites.
       • Malignancy-associated HLH (MA-HLH): Predominantly associated with T-cell lymphoma and NK/T-cell lymphoma, but also B-cell lymphomas, leukemias, and solid tumors.
       • Autoimmune/Rheumatic disease-associated HLH (MAS-HLH): Macrophage Activation Syndrome (MAS) is a form of sHLH occurring in the context of rheumatic diseases like Systemic Juvenile Idiopathic Arthritis (sJIA), Systemic Lupus Erythematosus (SLE), Kawasaki disease, and others.
       • Other: Metabolic diseases, drug-induced, post-transplant.

Pathophysiology

• Mechanism: The central defect in HLH is an impairment in the cytotoxic function of NK cells and CTLs. This leads to ineffective killing of target cells (e.g., virus-infected cells, tumor cells) and impaired downregulation of immune responses.

  • Cytotoxic Impairment: In primary HLH, specific genetic mutations directly affect granule-mediated cytotoxicity (e.g., perforin (PRF1), Munc13-4 (UNC13D), syntaxin-binding protein 2 (STXBP2)). In sHLH, severe triggers (e.g., massive viral load, malignancy) can temporarily overwhelm or suppress cytotoxic function.
  • Uncontrolled Activation: Impaired cytotoxicity results in persistent antigen presentation and cytokine release from activated macrophages and T cells. This leads to hyperproliferation and hyperactivation of T cells and macrophages.
  • Cytokine Storm: The unchecked activation results in a massive release of pro-inflammatory cytokines, including Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), Interleukin-10 (IL-10), and others. IFN-γ is a key mediator, driving macrophage activation and the systemic inflammatory response.
  • Organ Damage: These cytokines directly or indirectly cause the clinical manifestations:
    • Fever: Due to pyrogenic cytokines (IL-1, IL-6, TNF-α).
    • Cytopenias: Due to bone marrow suppression and hemophagocytosis in the bone marrow and spleen.
    • Hepatosplenomegaly: Infiltration of activated lymphocytes and macrophages.
    • Coagulopathy: Disseminated Intravascular Coagulation (DIC) due to cytokine-mediated endothelial damage and activation of the coagulation cascade, leading to hypofibrinogenemia.
    • Hyperferritinemia: Ferritin is an acute phase reactant, profoundly elevated by inflammatory cytokines.
    • Hypertriglyceridemia: Inhibition of lipoprotein lipase by TNF-α.
    • Neurological symptoms: Infiltration of the CNS by inflammatory cells, direct neurotoxicity of cytokines, and secondary complications like edema.

• Risk Factors:

  • Genetic Predisposition: Family history of HLH, identified germline mutations in PRF1, UNC13D, STXBP2, STX11, RAB27A, SH2D1A, XIAP, etc.
  • Severe Infections: Especially EBV, but also CMV, HIV, other herpesviruses, adenoviruses, parvovirus B19, bacterial sepsis, fungal infections, leishmaniasis.
  • Malignancies: Lymphomas (T-cell, NK-cell, B-cell), acute leukemias, solid tumors.
  • Autoimmune/Rheumatic Diseases: Systemic Juvenile Idiopathic Arthritis (sJIA), Systemic Lupus Erythematosus (SLE), Adult-onset Still's Disease (AOSD), Kawasaki disease, Crohn's disease, etc.
  • Immunosuppression/Immunodeficiency: Patients with primary immunodeficiencies or those undergoing transplant with severe immune activation.

• Protective Factors: There are no known "protective factors" against the development of HLH itself once a trigger is present or genetic predisposition exists. However, prompt recognition and initiation of appropriate immunosuppressive therapy are critical to prevent uncontrolled disease progression and subsequent organ damage, thereby improving outcomes.

Clinical Presentation

HLH can present with a wide spectrum of non-specific symptoms, making early diagnosis challenging. A high index of suspicion is crucial.

Signs and Symptoms

• Cardinal Features:

  • Persistent Fever: Often high-grade (>38.5°C or 101.3°F) and protracted, unresponsive to antibiotics.
  • Splenomegaly: Typically firm, palpable spleen, often progressing rapidly.
  • Cytopenias: Affecting at least two cell lines: anemia, thrombocytopenia, and/or neutropenia.
  • Neurological Symptoms: In a significant proportion of patients, particularly primary HLH.
  • Rash: Maculopapular, erythematous, or purpuric rash.

• Early Signs:

  • Persistent, unexplained fever for >7 days.
  • Fatigue, malaise, irritability.
  • Poor feeding (infants).
  • Early signs of organomegaly (e.g., mild hepatomegaly or splenomegaly).
  • Subtle cytopenias.

• Advanced Signs: Reflect multi-organ involvement and unchecked inflammation.

  • Severe Neurological Deterioration: Seizures, altered mental status, ataxia, cranial nerve palsies, hydrocephalus, nuchal rigidity.
  • Hemorrhagic Manifestations: Petechiae, purpura, epistaxis, gastrointestinal bleeding due to severe thrombocytopenia and/or coagulopathy (DIC).
  • Respiratory Distress: Due to pulmonary infiltrates or ARDS.
  • Jaundice/Liver Failure: Severe transaminitis, hyperbilirubinemia, impaired synthetic function.
  • Renal Dysfunction: Proteinuria, hematuria, acute kidney injury.
  • Edema: Peripheral edema, anasarca, due to capillary leak syndrome.
  • Lymphadenopathy: Generalised or localized.

• Atypical Presentations:

  • HLH without fever (rare, but possible in immunosuppressed patients).
  • Absence of splenomegaly at diagnosis (more common in adults or early stages).
  • Dominant presentation of a single organ involvement (e.g., isolated neurological HLH or purely cutaneous HLH) before systemic spread.
  • Normal leukocyte count or even leukocytosis, particularly in MAS or early stages.
  • Lack of hemophagocytosis on initial bone marrow biopsy (can be patchy or absent early in the disease).

Physical Examination

• Inspection:

  • General: Ill appearance, lethargy, irritability, poor perfusion.
  • Skin: Maculopapular rash (often non-specific), petechiae, purpura, jaundice, pallor.
  • Eyes: Conjunctival pallor.
  • Respiratory: Tachypnea, signs of respiratory distress.
  • Neurological: Altered consciousness, seizures, focal neurological deficits.

• Palpation:

  • Abdomen: Hepatomegaly (often tender), splenomegaly (frequently massive and firm).
  • Lymph Nodes: Generalized or localized lymphadenopathy.

• Special Tests:

  • Neurological Examination: Thorough assessment for motor deficits, sensory changes, cranial nerve palsies, cerebellar signs, signs of increased intracranial pressure.
  • Fundoscopy: For papilledema (if increased ICP suspected).

Diagnostic Approach

Diagnosis of HLH is based on a combination of clinical, laboratory, and histopathological findings. The HLH-2004 diagnostic criteria (or modified versions) are widely used. A high index of suspicion is paramount, especially in patients with unexplained fever, cytopenias, and organomegaly.

History Taking

• Key Questions:

  • Onset and Duration of Symptoms: When did fever, fatigue, rash, organomegaly start?
  • Fever Characteristics: Pattern, duration, response to antipyretics or antibiotics.
  • Infection History: Recent or recurrent infections (viral, bacterial, fungal), exposure risks (e.g., travel, animal contact). Specific questions about EBV, CMV.
  • Family History: Consanguinity, unexplained deaths in infancy/childhood, neurological problems, recurrent infections, other immune disorders. This is crucial for primary HLH.
  • Medical History:
    • Malignancy: Known diagnosis or symptoms suggestive of malignancy (e.g., unexplained weight loss, night sweats, lymphadenopathy).
    • Autoimmune/Rheumatic Diseases: Known diagnosis (e.g., sJIA, SLE) or symptoms suggestive of these conditions.
    • Immunodeficiency: History of recurrent severe infections, unusual pathogens.
    • Transplant Status: Recent solid organ or hematopoietic stem cell transplant.
  • Medication History: Recent drug exposures, new medications.
  • Neurological Symptoms: Any changes in behavior, seizures, altered consciousness, motor deficits.

• Red Flags:

  • Persistent high-grade fever of unknown origin (FUO) despite extensive workup.
  • New-onset or worsening bicytopenia/pancytopenia.
  • Rapidly progressive hepatosplenomegaly.
  • Unexplained neurological symptoms (seizures, altered mental status).
  • Markedly elevated ferritin levels (>10,000 ng/mL is highly suspicious, but not a strict cutoff).
  • Hypofibrinogenemia and/or elevated D-dimer (suggestive of DIC).
  • Presence of a known underlying trigger (e.g., severe EBV infection, aggressive lymphoma, active sJIA) with systemic inflammatory symptoms.

Laboratory Tests

HLH-2004 Diagnostic Criteria (requires 5 of 8 criteria OR molecular diagnosis consistent with HLH): 1. Fever ≥38.5°C 2. Splenomegaly 3. Cytopenias affecting ≥2 cell lines (Hb <9 g/dL, Platelets <100x10^9/L, Neutrophils <1.0x10^9/L) 4. Hypertriglyceridemia (fasting triglycerides ≥3.0 mmol/L [≥265 mg/dL]) and/or hypofibrinogenemia (fibrinogen <1.5 g/L) 5. Ferritin ≥500 ng/mL 6. Elevated sCD25 (soluble IL-2 receptor alpha) >2400 U/mL (reference ranges vary, confirm with lab) 7. Low or absent NK cell activity (reported as % NK cell lysis of target cells) 8. Hemophagocytosis in bone marrow, spleen, lymph nodes, or CSF (not required if other criteria met)

Note: For sHLH/MAS, specific MAS criteria (e.g., 2016 EULAR/ACR/PRINTO criteria for MAS in sJIA) may also be used, often emphasizing ferritin, triglycerides, platelets, LFTs, and ESR.

• First-Line (Initial Diagnostic Tests):

  • Complete Blood Count (CBC) with Differential: Often shows bicytopenia or pancytopenia (anemia, thrombocytopenia, neutropenia). White cell count can be normal or elevated initially.
  • Liver Function Tests (LFTs): Elevated AST/ALT, hyperbilirubinemia, elevated LDH.
  • Coagulation Profile: Prolonged PT/aPTT, low fibrinogen (<1.5 g/L is a criterion), elevated D-dimer (often >1000 ng/mL).
  • Ferritin: Markedly elevated, often >10,000 ng/mL, but >500 ng/mL is diagnostic criterion. High values are highly suggestive.
  • Triglycerides: Fasting triglycerides ≥3.0 mmol/L (≥265 mg/dL).
  • Erythrocyte Sedimentation Rate (ESR): Can be low, normal, or elevated. In MAS, a rapidly dropping ESR despite worsening clinical condition can be a clue.
  • C-Reactive Protein (CRP): Usually elevated.
  • Blood Culture: To rule out bacterial sepsis.
  • Virology Panel: EBV PCR (blood and CSF), CMV PCR (blood and CSF), HIV, parvovirus B19, VZV, HSV, HHV-6. EBV is a major trigger.
  • Autoimmune Markers: ANA, RF, anti-dsDNA, anti-CCP, ANCA (if rheumatic disease suspected).
  • Tumor Markers: LDH, beta-2 microglobulin, sIL-2Rα, potentially specific markers if malignancy is suspected.

• Confirmatory (Definitive Diagnostic Tests):

  • Soluble CD25 (sIL-2Rα): Elevated sCD25 (>2400 U/mL) is a key diagnostic criterion and correlates with disease activity. Note: Availability can be a challenge; send out early if not available locally.
  • NK Cell Activity: Low or absent NK cell lytic activity (often <5-10% lysis) is a hallmark of HLH and a diagnostic criterion. Send to specialized lab.
  • Perforin Expression: Flow cytometry to assess perforin expression in CTLs (decreased expression in some genetic forms of primary HLH).
  • Bone Marrow Aspiration and Biopsy: To look for hemophagocytosis (macrophages engulfing erythrocytes, leukocytes, platelets, or their precursors). Crucial: Hemophagocytosis is often patchy and can be absent in early stages; a negative biopsy does not rule out HLH. Review by an experienced hematopathologist is essential. Also helps rule out underlying malignancy.
  • Genetic Testing: For primary HLH mutations (PRF1, UNC13D, STXBP2, STX11, RAB27A, SH2D1A, XIAP, etc.). This is critical for confirming primary HLH and guiding long-term management (e.g., HSCT). Results can take weeks, so treatment should not be delayed.
  • CSF Analysis: If neurological symptoms are present: Cell count, protein, glucose, EBV PCR, HSV PCR, cytology for malignancy, sCD25. Often shows pleocytosis, elevated protein, and sometimes hemophagocytosis.

• Monitoring (Follow-up Tests):

  • Clinical Assessment: Daily monitoring of fever, organomegaly, neurological status, general condition.
  • CBC with Differential: Daily/alternate day initially, then weekly.
  • LFTs (AST/ALT, Bilirubin, LDH): Daily/alternate day initially, then weekly.
  • Coagulation Profile (PT/aPTT, Fibrinogen, D-dimer): Daily/alternate day initially, then weekly.
  • Ferritin: At least twice weekly initially, then weekly to assess treatment response. A decrease indicates response.
  • Soluble CD25: Weekly to bi-weekly, as available. Decreases with treatment response.
  • Triglycerides: Weekly.
  • Drug Levels: Cyclosporine A levels (target usually 150-250 ng/mL in HLH protocol), tacrolimus levels (if used).
  • Infection Surveillance: Regular screening for infections due to immunosuppression.

Imaging

• Recommended:

  • Abdominal Ultrasound or CT Scan: To assess hepatosplenomegaly, lymphadenopathy, and rule out other causes of abdominal symptoms.
  • Brain MRI with Contrast: Mandatory for all patients with HLH, even without neurological symptoms, to assess for CNS involvement (e.g., white matter lesions, periventricular lesions, meningeal enhancement, hydrocephalus). CNS involvement is common and impacts prognosis and treatment.
  • Chest X-ray: To assess for pulmonary infiltrates, pleural effusion.

• Advanced:

  • CT Chest/Abdomen/Pelvis: If malignancy is suspected as a trigger.
  • PET-CT: Can be useful in identifying underlying malignancies (especially lymphoma) and evaluating disease extent.
  • Echocardiogram: If cardiac dysfunction or pericardial effusion suspected.

Management

HLH is a medical emergency requiring prompt diagnosis and aggressive, multi-modal immunosuppressive therapy. Treatment should be initiated as soon as HLH is suspected, even before all diagnostic criteria are fully met or genetic results are available. The goal is to rapidly suppress the cytokine storm and control inflammation.

Acute Management

• Immediate (First-Hour Interventions):

  • Consultation: Emergent consultation with Hematology/Oncology, Intensive Care Unit (ICU) if unstable, Infectious Disease, and Rheumatology (if MAS suspected).
  • Stabilization: Assess airway, breathing, circulation. Provide supportive care as needed:
    • Fluid Resuscitation: For hypovolemia or shock.
    • Oxygen Support: If hypoxic.
    • Broad-spectrum Antibiotics: Initiate if infection is suspected, while awaiting culture results. Antifungal and antiviral agents may also be considered based on risk factors.
    • Blood Product Transfusions: For severe anemia (packed red blood cells, target Hb >7-8 g/dL), thrombocytopenia (platelets, target >20-50 x 10^9/L, higher for active bleeding or CNS involvement >100 x 10^9/L), and hypofibrinogenemia (cryoprecipitate).
    • Correction of Electrolytes/Metabolic Derangements: As indicated.

• Stabilization (Early Management Priorities):

  • Corticosteroids: High-dose corticosteroids are often the first step in empiric treatment to rapidly suppress inflammation. Dexamethasone is preferred due to better CNS penetration.
    • Dexamethasone: 10 mg/m²/day IV for 2 weeks, then tapered. (See HLH-2004 protocol below for specific dosing).
  • Identify and Treat Underlying Trigger: While immunosuppression is ongoing, continue the search for and treat any underlying infection (e.g., specific antivirals for EBV, Ganciclovir for CMV), malignancy (e.g., chemotherapy), or autoimmune disease (e.g., anakinra for MAS).

• Emergency (Crisis Management):

  • Disseminated Intravascular Coagulation (DIC): Treat underlying HLH. Transfuse blood products (platelets, cryoprecipitate) as needed.
  • Respiratory Failure: Mechanical ventilation for ARDS.
  • Neurological Emergencies:
    • Seizures: Anticonvulsants (e.g., lorazepam, levetiracetam).
    • Increased Intracranial Pressure (ICP): Management includes Dexamethasone, hypertonic saline/mannitol, CSF drainage (if hydrocephalus).
    • CNS HLH: Requires intrathecal therapy (methotrexate and corticosteroids) in addition to systemic therapy.

Chronic Management

The HLH-2004 protocol has been the standard of care for many years, primarily in pediatric HLH. Adaptations and newer agents are being increasingly used, especially for sHLH and refractory cases.

• Pharmacological:

  • HLH-2004 Protocol (for initial 8 weeks):

    • Dexamethasone: 10 mg/m²/day IV for 2 weeks, then tapered based on protocol. This is critical for rapid anti-inflammatory effect.
    • Etoposide (VP-16): 150 mg/m² IV once weekly for 8 weeks. Etoposide is an antineoplastic agent that targets rapidly dividing T cells and macrophages, reducing the inflammatory cell burden. It is myelosuppressive and hepatotoxic.
    • Cyclosporine A (CsA): Started at week 2 of therapy, typically 6-10 mg/kg/day orally in two divided doses, adjusted to achieve target trough levels (150-250 ng/mL). CsA inhibits T-cell activation and cytokine production.
    • Intrathecal Methotrexate (IT MTX): For patients with CNS involvement or positive CSF findings (initially or developed during therapy). Given usually weekly for 6 doses, then monthly. Dosing typically 10-12 mg depending on age. Intrathecal corticosteroids (hydrocortisone) may also be given.

  • Newer Agents and Strategies (Especially for sHLH/MAS and Refractory Cases):

    • Anakinra (Recombinant IL-1 receptor antagonist): For sHLH, particularly MAS associated with rheumatic diseases. Dosing typically 2-10 mg/kg/day subcutaneously or IV, often starting at 2-4 mg/kg/day and escalating. Can be very effective for MAS and has a favorable safety profile compared to etoposide.
    • Ruxolitinib (JAK1/2 Inhibitor): Used for refractory HLH or sHLH. Inhibits signaling pathways downstream of IFN-γ and other cytokines. Dosing typically 5-20 mg orally twice daily, adjusted for myelosuppression.
    • Emapalumab (Anti-IFN-γ monoclonal antibody): Approved for primary HLH with refractory, recurrent, or progressive disease. Blocks IFN-γ, a key cytokine in HLH. Dosing typically 1 mg/kg IV every 3 days, escalated as needed.
    • Alemtuzumab (Anti-CD52 monoclonal antibody): Used for refractory HLH, particularly in the context of XLP or T-cell lymphomas. Depletes T cells and B cells. Highly immunosuppressive. Dosing typically 0.3 mg/kg IV every other day for 3 doses, then 0.3 mg/kg IV weekly for 3-5 weeks.
    • IV Immunoglobulin (IVIG): Can be considered in sHLH for its immunomodulatory effects, especially if there is concurrent infection or hypogammaglobulinemia. Dosing typically 0.4-1 g/kg IV.
    • Rituximab: If EBV-associated HLH or B-cell lymphoma is the trigger. Targets CD20-positive B cells.

  • Treatment of Underlying Cause:

    • Infection: Specific antiviral (e.g., Ganciclovir for CMV, Acyclovir for HSV), antibacterial, antifungal, or antiparasitic therapy.
    • Malignancy: Chemotherapy specific to the type of lymphoma/leukemia.
    • Autoimmune Disease: Disease-modifying anti-rheumatic drugs (DMARDs), biological agents tailored to the specific autoimmune condition.

• Non-pharmacological:

  • Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): The only curative treatment for primary HLH and often considered for refractory sHLH. Indicated for all patients with primary HLH once initial disease control is achieved (typically after 8 weeks of therapy as per HLH-2004 protocol). Donor selection (matched sibling, matched unrelated, haploidentical) depends on availability and disease urgency.

• Monitoring (Long-term Follow-up):

  • Regular Clinical Review: To monitor for disease recurrence, complications, and treatment side effects.
  • Laboratory Monitoring: CBC, LFTs, renal function, ferritin, sCD25 (if available), CsA/other drug levels, infection markers.
  • Neurocognitive Assessment: For long-term neurological sequelae, especially in children.
  • Endocrine Monitoring: For pituitary dysfunction post-HSCT or due to CNS disease (e.g., thyroid function, growth hormone, adrenal function).
  • Immunological Assessment: For immune reconstitution post-HSCT.
  • Surveillance for Secondary Malignancies: Due to etoposide exposure.

Treatment Algorithms

• First-Line:

  1. High Suspicion of HLH: Initiate supportive care and high-dose Dexamethasone immediately (e.g., 10 mg/m²/day IV).
  2. Confirmation of HLH:
     • Primary HLH or Undifferentiated HLH: Initiate HLH-2004 Protocol (Dexamethasone + Etoposide + Cyclosporine A).
     • sHLH/MAS (particularly in rheumatic disease): High-dose Dexamethasone (or methylprednisolone pulse) ± IVIG. Consider Anakinra early if severe or steroids insufficient. Etoposide is reserved for severe or refractory cases of sHLH/MAS.
     • EBV-HLH: HLH-2004 protocol; consider adding Rituximab if severe or refractory.
     • MA-HLH: Treat the underlying malignancy in conjunction with HLH-specific therapy.

• Second-Line:

  • Inadequate Response to First-Line: (Defined as persistent clinical symptoms, rising ferritin/sCD25, worsening cytopenias after 2-4 weeks).
  • Primary HLH/Refractory Undifferentiated HLH: Consider dose escalation of existing agents, addition of Emapalumab, Ruxolitinib, or Alemtuzumab. Prepare for HSCT.
  • Refractory sHLH/MAS: Escalate Anakinra, add Ruxolitinib, or consider Etoposide if not already used. Identify and treat any missed underlying trigger more aggressively.

• Refractory Cases:

  • Primary HLH or High-Risk Recurrent sHLH: Allogeneic HSCT is the definitive treatment. Conditioning regimen should be carefully chosen.
  • Palliative Care: For patients with rapidly progressive or end-stage refractory disease where further aggressive therapy is unlikely to be beneficial.

Complications

• Common:

  • Infections: Due to immunosuppression from disease and treatment (bacterial, viral, fungal, parasitic). Prophylaxis is crucial.
  • Drug Toxicities:
    • Etoposide: Myelosuppression (neutropenia, thrombocytopenia), mucositis, alopecia, hepatotoxicity, secondary malignancies (leukemia).
    • Cyclosporine A: Nephrotoxicity, hepatotoxicity, hypertension, neurotoxicity (tremor, seizures), gingival hyperplasia.
    • Dexamethasone: Hyperglycemia, hypertension, fluid retention, opportunistic infections, growth suppression.
    • Anakinra/Ruxolitinib: Injection site reactions, increased infection risk, myelosuppression (ruxolitinib).
  • Bleeding: Due to thrombocytopenia and coagulopathy (DIC).

• Serious:

  • Multi-organ Failure: Hepatic, renal, respiratory, cardiac.
  • Disseminated Intravascular Coagulation (DIC): Leading to severe bleeding and thrombotic events.
  • Severe Neurological Damage: Permanent cognitive impairment, motor deficits, epilepsy, hydrocephalus.
  • Recurrence of HLH: Especially in primary HLH not treated with HSCT.
  • Fatal Outcomes: Despite aggressive treatment, mortality remains significant in severe cases or those with delayed diagnosis.

• Long-term:

  • Neurocognitive Impairment: Learning difficulties, memory problems, behavioral issues, especially in children with CNS involvement.
  • Endocrine Dysfunction: Hypothyroidism, adrenal insufficiency, growth hormone deficiency, often secondary to HSCT conditioning or CNS disease.
  • Growth Retardation: Due to chronic inflammation, steroid use, and HSCT.
  • Secondary Malignancies: Particularly acute myeloid leukemia (AML) associated with etoposide.
  • Infertility: Post-HSCT.
  • Chronic Organ Damage: Residual liver, kidney, or lung dysfunction.
  • Psychological Impact: Anxiety, depression, PTSD in patients and families.

Prognosis

Prognosis has significantly improved with standardized protocols like HLH-2004 but remains guarded, especially for primary and refractory cases.

• Factors Affecting Outcome:

  • Type of HLH: Primary HLH generally has a poorer prognosis without HSCT. sHLH prognosis depends heavily on the underlying trigger and its treatability.
  • Age at Onset: Very young children (especially infants) with primary HLH can have a more aggressive course.
  • Presence of CNS Involvement: Significantly worsens prognosis.
  • Response to Initial Therapy: Early and complete response predicts better outcomes.
  • Identification and Treatment of Underlying Trigger: Crucial for sHLH.
  • Genetic Mutation: Some primary HLH mutations (e.g., STXBP2) are associated with higher neurological involvement and poorer outcomes.
  • Availability of HSCT: For primary HLH, HSCT is curative and improves long-term survival.

• Survival:

  • Primary HLH: Before HLH-2004, median survival was less than a year. With HLH-2004 followed by HSCT, 5-year overall survival rates are now approximately 60-70%.
  • Secondary HLH: Highly variable. Survival rates depend on the underlying trigger, severity of presentation, and response to therapy. MA-HLH generally has a worse prognosis due to aggressive nature of underlying malignancy. MAS-HLH generally has a better prognosis if recognized and treated promptly.

• Quality of Life: Can be significantly impacted by long-term neurological sequelae, endocrine dysfunction, and complications of HSCT. Regular multidisciplinary follow-up is essential to address these issues.

Prevention

• Primary Prevention:

  • Genetic Counseling: For families with a known history of primary HLH. This can identify carriers and allow for prenatal diagnosis or preimplantation genetic diagnosis.
  • No specific measures exist to prevent the initial occurrence of HLH in individuals without a known genetic predisposition or identifiable trigger.

• Secondary Prevention (Early Detection and Intervention):

  • High Index of Suspicion: Crucial for prompt diagnosis, especially in patients presenting with prolonged unexplained fever, cytopenias, and organomegaly.
  • Rapid Workup: Expedited diagnostic testing for HLH in at-risk populations (e.g., sJIA patients with worsening symptoms, patients with severe EBV infection, patients with lymphoma).
  • Screening in Families: For siblings of patients with primary HLH, genetic screening and baseline immunological testing (NK cell activity, perforin expression) can allow for early intervention if symptoms develop.

• Tertiary Prevention (Preventing Complications and Recurrence):

  • Allogeneic HSCT: For all patients with primary HLH (after achieving initial disease control) to prevent recurrence and progression.
  • Close Monitoring: For recurrence or development of complications in all patients who have experienced HLH, particularly during periods of immunosuppression or trigger exposure.
  • Management of Underlying Conditions: Aggressive and appropriate treatment of any identified underlying infection, malignancy, or autoimmune disease to prevent recurrence of sHLH.
  • Prophylactic Immunosuppression: In some high-risk situations (e.g., after EBV-HLH), ongoing low-dose immunosuppression may be considered.

Special Populations

• Pediatric:

  • Dominant Age Group for Primary HLH: HLH-2004 protocol was developed and primarily validated in children.
  • Genetic Testing: Essential in all pediatric HLH cases to rule out primary forms.
  • CNS Involvement: More common and often more severe in children, requiring aggressive CNS-directed therapy.
  • Long-term Neurocognitive Follow-up: Crucial for children due to potential impact on development.

• Geriatric:

  • Predominantly Secondary HLH: Often malignancy-associated (MA-HLH) or infection-associated.
  • Diagnostic Challenge: HLH can be overlooked due to multiple comorbidities and atypical presentations.
  • Treatment Challenges: Older patients may tolerate aggressive chemotherapy (like etoposide) poorly due to decreased organ reserve and comorbidities. Dosing adjustments and careful monitoring for toxicity are essential.
  • Prognosis: Generally poorer due to comorbidities, advanced age, and often aggressive underlying triggers.

• Pregnancy:

  • Extremely Rare: HLH during pregnancy is a high-risk condition for both mother and fetus.
  • Diagnostic Overlap: Can be confused with preeclampsia, HELLP syndrome, or severe infections.
  • Treatment Modifications: Etoposide is teratogenic and contraindicated in pregnancy. Corticosteroids and IVIG are generally considered safer options. Cyclosporine A has been used, but fetal monitoring is required. Multidisciplinary team management (hematology, maternal-fetal medicine) is critical. Early delivery may be considered if maternal condition deteriorates.

• Comorbidities:

  • Renal/Hepatic Impairment: Requires significant dosage adjustments for medications like etoposide, cyclosporine A, and other agents. Careful monitoring of drug levels and organ function is paramount.
  • Immunocompromised Patients: Increased risk of opportunistic infections. Careful antimicrobial prophylaxis is necessary.
  • Cardiovascular Disease: Monitor for fluid overload, hypertension (especially with corticosteroids/CsA).

Clinical Pearls

• Diagnostic:

  • Think HLH: In any patient (especially child) with prolonged unexplained fever, cytopenias (bicytopenia/pancytopenia), and organomegaly (hepatosplenomegaly).
  • Ferritin is Key: A serum ferritin >10,000 ng/mL is highly suspicious for HLH, although the diagnostic criterion is >500 ng/mL. A rising ferritin is more important than a single value.
  • Soluble CD25 (sIL-2Rα): This is the most specific laboratory marker for HLH activity and directly correlates with disease severity and response to treatment. Get it early if available.
  • Bone Marrow Biopsy: While helpful for showing hemophagocytosis and ruling out malignancy, a negative biopsy does NOT exclude HLH, as hemophagocytosis can be patchy or absent early on. It should never delay treatment if clinical suspicion is high and other criteria are met.
  • Don't Forget the Brain: CNS involvement is common even in asymptomatic patients. Always get a baseline brain MRI and consider CSF studies.

• Treatment:

  • Time is Tissue: HLH is a medical emergency. Do not delay treatment while awaiting all confirmatory tests, especially genetic results. Initiate empiric Dexamethasone ± Etoposide if HLH is highly suspected.
  • HLH-2004 Protocol: Remains the backbone of treatment for primary HLH and severe sHLH. Adherence to the protocol is associated with improved outcomes.
  • Tailor for sHLH: For sHLH, especially MAS, newer agents like Anakinra and Ruxolitinib can be highly effective, often with fewer side effects than etoposide, and should be considered early. Focus on identifying and treating the underlying trigger.
  • CNS Penetration: Dexamethasone has good CNS penetration; Etoposide's is poor, necessitating intrathecal therapy for CNS involvement.
  • HSCT is Curative for Primary HLH: Prepare for HSCT early once a diagnosis of primary HLH is confirmed and initial disease control is achieved.

• Pitfalls:

  • Delayed Diagnosis: The most common and dangerous pitfall, leading to irreversible organ damage and increased mortality. HLH often mimics severe sepsis, severe viral infection, or other inflammatory conditions.
  • Inadequate Workup for Underlying Cause: Failure to identify the trigger for sHLH (e.g., occult lymphoma, atypical infection) can lead to treatment failure and recurrence.
  • Under-dosing or Premature Discontinuation of Therapy: Can lead to rebound inflammation and a more refractory disease course.
  • Overlooking CNS Involvement: Failure to screen for or treat CNS HLH can result in devastating neurological sequelae.
  • Failure to Consider Primary HLH: In adults, primary HLH mutations can sometimes present later in life, especially if triggered by severe infection. Genetic testing should be considered broadly.

Recent Updates

• Guidelines:

  • HLH-2004 Protocol: Remains the primary standard for treatment of primary HLH, with ongoing modifications and refinements.
  • 2016 EULAR/ACR/PRINTO Criteria for MAS in sJIA: These are specific diagnostic criteria for MAS in the setting of systemic juvenile idiopathic arthritis, emphasizing rapid changes in platelets, ESR, and LFTs, in addition to typical HLH markers. These are widely used for early detection of MAS.

• Evidence:

  • Targeted Therapies:
    • Emapalumab (anti-IFN-γ): Approved in the US and Europe for primary HLH refractory to or intolerant of conventional therapy, or with recurrent/progressive disease. Clinical trials have shown significant response rates.
    • Ruxolitinib (JAK1/2 inhibitor): Increasing evidence supports its use in refractory HLH (both primary and secondary) and in sHLH/MAS, by blocking key cytokine signaling. Ongoing trials are further defining its role and optimal timing.
    • Anakinra (IL-1 antagonist): Well-established as a safe and effective first-line agent for MAS associated with rheumatic diseases, often sparing the use of etoposide.
  • Genetic Testing: Broader availability and next-generation sequencing have improved the ability to rapidly diagnose genetic forms of HLH, influencing treatment decisions and HSCT planning.

• Controversies:

  • Optimal Treatment for sHLH/MAS: While corticosteroids are universal, the role and timing of etoposide versus newer targeted therapies (Anakinra, Ruxolitinib) are debated. The need to balance efficacy against toxicity for specific triggers is ongoing.
  • Role of HSCT in Secondary HLH: Whether HSCT is indicated for certain types of sHLH (e.g., recurrent EBV-HLH, refractory MA-HLH in remission) remains an area of active research and clinical discussion.
  • Definition of Refractory HLH: Clear, universally accepted definitions are still evolving, which impacts the timing and initiation of second-line and third-line therapies.
  • Long-term Surveillance: Optimal long-term follow-up strategies for neurocognitive, endocrine, and immunological sequelae, especially in survivors of primary HLH and HSCT recipients, are still being refined.

Key References

• Guidelines:

  • HLH-2004 Protocol: Henter JI, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-2004 protocol. Blood. 2007;120(13):2546-2557.
  • MAS in sJIA Guidelines: Ravelli A, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis & Rheumatology. 2016;68(3):566-576.

• Studies:

  • Emapalumab Trial: Jordan MB, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2018;380(7):608-618.
  • Ruxolitinib in HLH: Wang X, et al. Ruxolitinib for refractory hemophagocytic lymphohistiocytosis. Leukemia. 2020;34(11):3125-3132.
  • Anakinra in MAS: Minoia F, et al. Macrophage activation syndrome in juvenile idiopathic arthritis: new insights from the Eurofever/EuroMAS registry. Ann Rheum Dis. 2017;76(11):1858-1864.

• Reviews:

  • Risma KA, et al. Hemophagocytic Lymphohistiocytosis: Genetics, Pathophysiology, and Treatment. Semin Immunopathol. 2020;42(2):161-178.
  • Rosado FG, et al. Hemophagocytic Lymphohistiocytosis: An Update on Diagnosis and Pathogenesis. Am J Clin Pathol. 2018;149(4):303-313.
  • La Rosée P, et al. Hemophagocytic lymphohistiocytosis (HLH) in adults: clinical characteristics, treatment and prognostic factors. Ann Hematol. 2019;98(4):815-827.